BIIB122 for Parkinson's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
How does the drug BIIB122 differ from other Parkinson's disease treatments?
BIIB122 (DNL151) is unique because it targets the FBXO7 protein, which is involved in maintaining brain neurons and is linked to the pathogenesis of Parkinson's disease. This approach is different from traditional treatments that primarily focus on managing symptoms rather than addressing underlying cellular mechanisms.12345
Who Is on the Research Team?
Danna Jennings, MD
Principal Investigator
Denali Therapeutics
Are You a Good Fit for This Trial?
This trial is for people aged 30-80 with Parkinson's Disease who carry a specific genetic change (LRRK2 variant) that increases LRRK2 activity. They must meet the clinical criteria for PD diagnosis and have verified genetic test results showing they have this mutation.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either BIIB122 225 mg or a matching placebo once daily for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- BIIB122
Find a Clinic Near You
Who Is Running the Clinical Trial?
Denali Therapeutics Inc.
Lead Sponsor
Biogen
Industry Sponsor
Daniel Quirk
Biogen
Chief Medical Officer
MD
Christopher A. Viehbacher
Biogen
Chief Executive Officer since 2022
Graduated from Queen's University, Kingston, Ontario, Canada